Insulin preparations: RMOC recommendations of safety considerations for formulary decision making

At its meeting on 18th April 2018 the Regional Medicines Optimisation Committee (RMOC) (Midlands and East) reviewed issues pertaining to safety considerations when adopting any insulin preparation onto a local formulary.

The RMOC programme has now issued guidance to formulary committees/ Area Prescribing Committees on this subject.

The guidance is also available as a checklist which is intended to be completed as part of the evidence-gathering process alongside clinical and cost-effectiveness data.

Acute CareCare homesCommunity Health ServicesDiabetesInsulin aspartInsulin aspart biphasicInsulin degludecInsulin degludec + LiraglutideInsulin detemirInsulin glargineInsulin glulisineInsulin humanInsulin isophane biphasic humanInsulin isophane biphasic porcineInsulin isophane bovineInsulin isophane humanInsulin isophane porcineInsulin lisproInsulin lispro biphasicInsulin mixed bovineInsulin protamine zinc bovineInsulin soluble bovineInsulin soluble humanInsulin soluble porcineInsulin zinc crystalline humanInsulin zinc mixed humanNewsPrimary CareRMOC medicines optimisation recommendations and resourcesRMOC recommendations and resourcesTransfer of care

Attachments